← Back to Search

Exon Skipping Agent

Viltolarsen for Duchenne Muscular Dystrophy

Phase 3
Waitlist Available
Research Sponsored by NS Pharma, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be younger than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline to 48 weeks of treatment
Awards & highlights
Pivotal Trial

Summary

This trial is testing Viltolarsen, an IV medication given regularly, in boys with Duchenne muscular dystrophy who have specific genetic mutations. The medication helps the body skip over a faulty gene part to improve muscle function.

Eligible Conditions
  • Duchenne Muscular Dystrophy

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline to 48 weeks of treatment
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline to 48 weeks of treatment for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
TTSTAND
Secondary study objectives
6MWT
Hand-held dynamometer
NSAA
+2 more

Side effects data

From 2023 Phase 2 trial • 20 Patients • NCT04956289
30%
COVID-19
25%
Diarrhoea
20%
Haematuria
20%
Headache
15%
Nasopharyngitis
15%
Upper respiratory tract infection
10%
Pain in extremity
10%
Abdominal pain upper
10%
Food poisoning
10%
Pyrexia
10%
Joint injury
10%
Influenza
10%
Rhinitis
5%
Hypertension
5%
Gait inability
5%
Myalgia
5%
Toothache
5%
Tension headache
5%
Blister
5%
Rash
5%
Vomiting
5%
Pharyngitis
5%
Drug hypersensitivity
5%
Nephrolithiasis
5%
Urine cytology abnormal
5%
Non-cardiac chest pain
5%
Contusion
5%
Ligament sprain
5%
Back pain
5%
Angina pectoris
5%
Otitis media
5%
Tachycardia
5%
Protein urine
5%
Nasal congestion
5%
Oropharyngeal pain
100%
80%
60%
40%
20%
0%
Study treatment Arm
Viltolarsen 80mg/kg

Awards & Highlights

Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: ViltolarsenExperimental Treatment1 Intervention
Patients amenable to exon 53 skipping will receive viltolarsen intravenous (IV) infusions, weekly, at 80 mg/kg for up to 48 weeks.
Group II: PlaceboPlacebo Group1 Intervention
Patients amenable to exon 53 skipping will receive placebo intravenous (IV) infusions, weekly, for up to 48 weeks.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Viltolarsen
2021
Completed Phase 3
~100

Find a Location

Who is running the clinical trial?

NS Pharma, Inc.Lead Sponsor
13 Previous Clinical Trials
384 Total Patients Enrolled
Nippon Shinyaku Co., Ltd.Industry Sponsor
13 Previous Clinical Trials
419 Total Patients Enrolled

Media Library

Viltolarsen (Exon Skipping Agent) Clinical Trial Eligibility Overview. Trial Name: NCT04060199 — Phase 3
Duchenne Muscular Dystrophy Research Study Groups: Viltolarsen, Placebo
Duchenne Muscular Dystrophy Clinical Trial 2023: Viltolarsen Highlights & Side Effects. Trial Name: NCT04060199 — Phase 3
Viltolarsen (Exon Skipping Agent) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04060199 — Phase 3
~14 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top